Collegium Pharmaceutical (COLL) Price Target Raised to $28.00 at Needham & Company LLC
Collegium Pharmaceutical (NASDAQ:COLL) had its target price upped by Needham & Company LLC from $25.00 to $28.00 in a report issued on Tuesday. Needham & Company LLC currently has a buy rating on the specialty pharmaceutical company’s stock. The analysts noted that the move was a valuation call.
Several other research firms have also commented on COLL. Zacks Investment Research upgraded Collegium Pharmaceutical from a hold rating to a buy rating and set a $16.00 price target on the stock in a report on Monday, November 13th. Jefferies Group lifted their price target on Collegium Pharmaceutical to $27.00 and gave the stock a buy rating in a report on Tuesday. HC Wainwright reiterated a buy rating and set a $21.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, November 8th. Finally, Piper Jaffray Companies reiterated a buy rating and set a $14.00 price target on shares of Collegium Pharmaceutical in a report on Friday, September 8th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $22.67.
Shares of Collegium Pharmaceutical (COLL) traded up $0.80 during mid-day trading on Tuesday, reaching $17.74. The company’s stock had a trading volume of 2,355,300 shares, compared to its average volume of 506,368. Collegium Pharmaceutical has a 12 month low of $7.37 and a 12 month high of $20.92.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.28. The company had revenue of $11.95 million for the quarter, compared to analyst estimates of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The firm’s revenue for the quarter was up 2814.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.13) EPS. equities research analysts forecast that Collegium Pharmaceutical will post -2.56 earnings per share for the current fiscal year.
In other news, insider Alison B. Fleming sold 4,601 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total transaction of $79,367.25. Following the completion of the transaction, the insider now directly owns 28,513 shares of the company’s stock, valued at $491,849.25. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total value of $776,500.00. Following the sale, the chief executive officer now owns 558,987 shares of the company’s stock, valued at approximately $8,681,068.11. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 58,630 shares of company stock valued at $924,360. 25.76% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the stock. Credit Suisse AG lifted its stake in Collegium Pharmaceutical by 9.4% during the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after purchasing an additional 1,173 shares during the last quarter. American International Group Inc. lifted its stake in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares during the last quarter. Nationwide Fund Advisors lifted its stake in Collegium Pharmaceutical by 27.8% in the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after buying an additional 2,802 shares during the last quarter. Royal Bank of Canada lifted its stake in Collegium Pharmaceutical by 12.7% in the second quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock valued at $365,000 after buying an additional 3,285 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Collegium Pharmaceutical by 3.4% in the first quarter. Geode Capital Management LLC now owns 146,568 shares of the specialty pharmaceutical company’s stock valued at $1,474,000 after buying an additional 4,866 shares during the last quarter. Hedge funds and other institutional investors own 79.98% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/12/06/collegium-pharmaceutical-coll-price-target-raised-to-28-00-at-needham-company-llc.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.